Summary
A Phase I trial of intraperitoneally administered 5-FU and citrovorum factor was performed in eight patients with a variety of malignancies. Both drugs were given according to a single weekly dose schedule in a volume estimated to be 2000 cc, including residual ascites. Citrovorum factor 50 mg was given first, immediately followed by 5-FU 1000–3400 mg, according to a dose-escalating schedule. Myelosuppression proved to be the dose-limiting toxicity, though mucositis, diarrhea, nausea, and abdominal pain were also produced. Six patients failed to respond to therapy. One patient with malignant mesothelioma showed a significant decrease in the production of malignant ascites and a transient conversion of peritoneal fluid cytologies from positive to negative, while a second patient with pancreatic cancer showed conversion of peritoneal fluid cytologies from positive to negative and demonstrated an objective partial response of an hepatic metastasis. Dosage adjustment according to body surface area would seem indicated by the toxicity data, with a 5-FU dose of 1200 mg/m2 body surface area and citrovorum factor 50 mg/m2 being recommended for Phase II trials of this combination of drugs given according to this weekly schedule.
Similar content being viewed by others
References
Dedrick RL, Myers CE, Bungay PM, DeVita VT: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62(1):1–11, 1978
Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker Jr RW, Meyers CE: Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 41:1916–1922, 1981
Gyves JW, Ensminger WD, Stetson P, Niederhuber JE, Meyer M, Walker S, Janis M, Gilbertson S: Constant intraperitoneal 5-fluorouracil infusion through a totally implanted system. Clin Pharmacol Ther 35(l):83–89, 1984
Howell SB, Pfeifle CE, Wung WE, Olshen RA: Intraperitoneal cis-Diarnmine-dichloroplatinum with systemic thiosulfite protection. Cancer Res 43:1426–1431, 1983
Evans RM, Laskin JD, Hakala MT: Effects of excess folates in deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41:3288–3295, 1981
Machover D, Schwartzenberg C, Goldschmidt E, Tourani JM, Michalski B, Hagat M, Dorval T, Misset JL, Jasmin C, Maral R, Mathé G: Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with highdose folinic acid. Proc Am Soc Clin Oncol 1:33, 1982
Cunningham J, Bukowski RM, Budd GT, Weick JK, Purvis JD: 5-fluorouracil and folinic acid: a phase I-II trial in gastrointestinal malignancy. Invest New Drugs 2:391–395, 1984
Taylor I, Rouling J, West C: Adjuvant cytotoxic liver perfusion for colorectal cancer. Br J Surg 66(12):833–837, 1979
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Budd, G.T., Schreiber, M.J., Steiger, E. et al. Phase I trial of intraperitoneal chemotherapy with 5-fluorouracil and citrovorum factor. Invest New Drugs 4, 155–158 (1986). https://doi.org/10.1007/BF00194595
Issue Date:
DOI: https://doi.org/10.1007/BF00194595